Boardroom Media (CFO News)
At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Germany based CFO’ operating in the Biopharma space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected]
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Pierre Kemula
CFO of CureVac
joined CureVac in October 2016. Before joining CureVac, he was Chief Financial Officer of Pixium Vision where he successfully contributed to the listing of the company on Euronext in Paris, and Vice President Corporate Finance, Treasury and Financial Markets at Ipsen. He had earlier worked with major strategy consulting firms (Roland Berger, Bossard Consultants and Gemini Consulting). He holds a Bachelor of Science in Management Sciences from the London School of Economics (LSE) in the United Kingdom.
Follow Pierre Kemula:
About CureVac: CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA.
Thomas Dürre
Chief Financial Officer of Isotopen Technologien München
Thomas accepted the position as Chief Financial Officer at ITM Isotopen Technologien München AG in April 2016. Before that he worked for 3 years as Senior Vice President at Software AG and was responsible for all aspects of Global Integration Management. Prior to this he was CFO at alfabet AG for 15 years and headed the successful sale and merger of alfabet AG to Software AG. Thomas started his career in 1991 at Ernst & Young and worked from 1996 until 1998 as Controller Germany for the US based international waste management company BFI. Thomas has 25 years of work experience in finance, especially in the international expansion and growth of start-ups and preparation as well as execution of exit strategies in private equity companies. He holds a Masters Degree in Business Administration (Dipl.-Kfm.) from the University of Cologne (Germany).
Follow Thomas Dürre:
About Isotopen Technologien München: Isotopen Technologien München is a privately held biotechnology and radiopharmaceutical group of companies.
Thomas Hoffmann
Chief Financial Officer of Phenex Pharmaceuticals
Follow Thomas Hoffmann:
About Phenex Pharmaceuticals: Phenex Pharmaceuticals is a drug discovery and development company focused on developing novel pharmaceuticals.
Thomas Pfaadt
CFO and Managing Director of c-LEcta
Thomas joined c-LEcta in 2018 as CFO and managing director. Previously he worked for a private equity owned operator of rehabilitation clinics in Berlin as well as for a family owned integrated healthcare group and was responsible for M&A respectively for corporate finance and investor relations. Before that he gained experiences as banker and consultant with a strong focus on the healthcare sector. Thomas studied business administration at Goethe University in Frankfurt/M and at University of Southampton/UK.
Follow Thomas Pfaadt:
About c-LEcta: c-LEcta operates as a biotechnology company focusing on enzyme engineering and bioprocess development for regulated markets.
Thomas Pfaadt
CFO and Managing Director of c-LEcta
Thomas joined c-LEcta in 2018 as CFO and managing director. Previously he worked for a private equity owned operator of rehabilitation clinics in Berlin as well as for a family owned integrated healthcare group and was responsible for M&A respectively for corporate finance and investor relations. Before that he gained experiences as banker and consultant with a strong focus on the healthcare sector. Thomas studied business administration at Goethe University in Frankfurt/M and at University of Southampton/UK.
Follow Thomas Pfaadt:
About c-LEcta: c-LEcta operates as a biotechnology company focusing on enzyme engineering and bioprocess development for regulated markets.
Jaska Harm
CFO of LXP Group GmbH
Jaska H. Harm is the CFO of maxbiogas GmbH, a biotech energy startup based in the region Berlin-Brandenburg. With its pre-treatment-process maxbiogas offers an unique state-of-the-art solution to separate efficiently lignin and cellulose from plant residues. At maxbiogas Jaska is in charge of business development, financials and fundraising. Prior to this he has been an advisor in the international real estate and energy industry for almost 20 years. Among other he has founded and managed a district heat supplier and has been advising German and US based open and closed end funds as well as international family offices in all kind of phases in the life cycle of an investment. He holds a Masters Degree in Business from the University of Saarland in Southern Germany and speaks fluently German, Finnish, English, and some Swedish.
Follow Jaska Harm:
About LXP Group GmbH, Maxbiogas: Revolutionary process for utilization of 2G biomass
